Category
Dr
James
Watson
Associate Director
Co-Lead Malaria Chemoprevention Theme
Email
Research Theme
Malaria
Chagas
WWARN
James Watson joined IDDO in March 2023 as Associate Director.
He is a Sir Henry Dale Fellow funded by the Wellcome Trust working on improving the diagnosis and treatment of severe falciparum malaria.
James is a statistician by training and previously worked at the Mahidol Oxford Tropical Medicine Research Unit in Bangkok for seven years before moving to the Oxford University Clinical Research Unit in Viet Nam.
His research interests also include the radical cure of Plasmodium vivax malaria, SARS-CoV-2 antivirals, Chagas disease, snakebite and adaptive trial design.
All Publications
Graphing and reporting heterogeneous treatment effects through reference classes.
Watson, J., & Holmes, C. (2020). Trials, 21(1), 386.
A cautionary note on the use of unsupervised machine learning algorithms to characterise malaria parasite population structure from genetic distance matrices
Watson, J., Taylor, A., Ashley, E., Dondorp, A., Buckee, C., White, N., & Holmes, C. (2020).
Concomitant bacteremia in adults with severe falciparum malaria
Phu, N., Day, N., Tuan, P., Mai, N., Chau, T., Van Chuong, L., Vinh, H., Loc, P., Sinh, D., Hoa, N., Waller, D., Wain, J., Jeyapant, A., Watson, J., Farrar, J., Hien, T., Parry, C., & White, N. (2020). Clinical Infectious Diseases, 71(9), e465 - e470.
A molecular barcode to inform the geographical origin and transmission dynamics of Plasmodium vivax malaria
Diez Benavente, E., Campos, M., Phelan, J., Nolder, D., Dombrowski, J., Marinho, C., Sriprawat, K., Taylor, A., Watson, J., Roper, C., Nosten, F., Sutherland, C., Campino, S., & Clark, T. (2020). PLoS Genetics, 16(2).
Machine learning analysis plans for randomised controlled trials: detecting treatment effect heterogeneity with strict control of type I error.
Watson, J., & Holmes, C. (2020). Trials, 21(1), 156.
A semi-supervised learning framework for quantitative structure-activity regression modelling
Watson, O., Cortes-Ciriano, I., & Watson, J. (2020). In arXiv.
A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: application to a dose-finding trial for a novel Russell’s viper antivenom in Myanmar
Watson, J., Lamb, T., Holmes, J., Warrell, D., Thwin, K., Aung, Z., Nwe, M., Smithuis, F., & Ashley, E. (2020).
Concentration-dependent mortality of chloroquine in overdose
Watson, J., Tarning, J., Hoglund, R., Baud, F., Mégarbane, B., Clemessy, J.-L., & White, N. (2020).
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Horby, P., Mafham, M., Linsell, L., Bell, J., Staplin, N., Emberson, J., Wiselka, M., Ustianowski, A., Elmahi, E., Prudon, B., Whitehouse, A., Felton, T., Williams, J., Faccenda, J., Underwood, J., Baillie, K., Chappell, L., Faust, S., Jaki, T., … Landray, M. (2020).
The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos
Von Seidlein, L., Peerawaranun, P., Mukaka, M., Nosten, F., Nguyen, T.-N., Hien, T., Tripura, R., Peto, T., Pongvongsa, T., Phommasone, K., Mayxay, M., Imwong, M., Watson, J., Pukrittayakamee, S., Day, N., & Dondorp, A. (2019). Malaria Journal, 18.
Resolving the cause of recurrent Plasmodium vivax malaria probabilistically
Taylor, A., Watson, J., Chu, C., Puaprasert, K., Duanguppama, J., Day, N., Nosten, F., Neafsey, D., Buckee, C., Imwong, M., & White, N. (2019). Nature Communications, 10(1).
Investigating causal pathways in severe falciparum malaria: A pooled retrospective analysis of clinical studies.
Leopold, S., Watson, J., Jeeyapant, A., Simpson, J., Phu, N., Hien, T., Day, N., Dondorp, A., & White, N. (2019). PLoS Medicine, 16(8).
The haematological consequences of plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
Commons, R., Simpson, J., Thriemer, K., Chu, C., Douglas, N., Abreha, T., Alemu, S., Añez, A., Anstey, N., Aseffa, A., Assefa, A., Awab, G., Baird, K., Barber, B., Borghini-Fuhrer, I., D’Alessandro, U., Dahal, P., Daher, A., De Vries, P., … Guerin, P. (2019). BMC Medicine, 17.
Tafenoquine versus primaquine to prevent relapse of plasmodium vivax malaria
Watson, J., & Taylor, A. (2019). New England Journal of Medicine, 380(19), 1875-1876.
A decision-theoretic approach to the evaluation of machine learning algorithms in computational drug discovery
Watson, O., Cortes-Ciriano, I., Taylor, A., & Watson, J. (2019). Bioinformatics, 35(22), 4656-4663.
Pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole
Watson, J., Strub-Wourgraft, N., Tarral, A., Ribeiro, I., Tarning, J., & White, N. (2019). Antimicrobial Agents and Chemotherapy, 63(4), e02515 - 18.
Collider bias and the apparent protective effect of glucose-6-phosphate dehydrogenase deficiency on cerebral malaria
Watson, J., Leopold, S., Simpson, J., Day, N., Dondorp, A., & White, N. (2019). ELife, 8.
Assessing non-adherence in non-inferiority trials: implications from a simulation study
Mo, Y., Lim, C., Watson, J., & Cooper, B. (2019). TRIALS, 20.
Estimating the probable cause of recurrence in Plasmodium vivax malaria: relapse, reinfection or recrudescence?
Taylor, A., Watson, J., Chu, C., Puaprasert, K., Duanguppama, J., Day, N., Nosten, F., Neafsey, D., Buckee, C., Imwong, M., & White, N. (2018).
A pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole
Watson, J., Strub-Wourgraft, N., Tarral, A., Ribeiro, I., Tarning, J., & White, N. (2018).
Chloroquine versus hihydroartemisinin-piperaquine with standard high-dose Primaquine given either for 7 days or 14 days in Plasmodium vivax malaria
Chu, C., Phyo, A., Turner, C., Win, H., Poe, N., Yotyingaphiram, W., Thinraow, S., Wilairisak, P., Raksapraidee, R., Carrara, V., Paw, M., Wiladphaingern, J., Proux, S., Bancone, G., Sriprawat, K., Lee, S., Jeeyapant, A., Watson, J., Tarning, J., … White, N. (2018). Clinical Infectious Diseases, 68(8), 1311-1319.
A decision theoretic approach to model evaluation in computational drug discovery
Watson, O., Cortes-Ciriano, I., Taylor, A., & Watson, J. (2018). In arXiv.
Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in plasmodium vivax malaria
Chu, C., Phyo, A., Lwin, K., Win, H., San, T., Aung, A., Raksapraidee, R., Carrara, V., Bancone, G., Watson, J., Moore, K., Wiladphaingern, J., Proux, S., Sriprawat, K., Winterberg, M., Cheah, P., Chue, A., Tarning, J., Imwong, M., … White, N. (2018). Clinical Infectious Diseases, 67(10), 1543-1549.
Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria
Watson, J., Taylor, W., Bancone, G., Chu, C., Jittamala, P., & White, N. (2018). PLoS Neglected Tropical Diseases, 12(4), e0006440.